Moderna Stock Doubles on Cancer Breakthrough: Here’s What It Means
A Phase 3 win against the standard of care sent the biotech's shares up 131% and left short sellers down $4.8 billion.
Story
Decrypt · Crypto & Web3
Join the conversation
Discuss the story with the TraceFeed community.
No comments yet. Be the first to add a perspective.